Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

Immune checkpoint inhibitors have revolutionized cancer treatment due to their undeniable efficacy, but a range of new adverse events (AE) has emerged. In particular, cardiac toxicity is a potentially fatal AE, and introduces new challenges regarding its underlying molecular mechanisms of occurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin Huertas, Roberto, Saavedra Serrano, Cristina, Perna, Cristian, Ferrer Gómez, Ana, Alonso Gordoa, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529611/
https://www.ncbi.nlm.nih.gov/pubmed/31191015
http://dx.doi.org/10.2147/CMAR.S185202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529611/
https://www.ncbi.nlm.nih.gov/pubmed/31191015
http://dx.doi.org/10.2147/CMAR.S185202

Ejemplares similares